Diabetes Care, Vol 22, Issue 7 1186-1190, Copyright © 1999 by American Diabetes Association

ARTICLES

Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes

TJ Berg, O Snorgaard, J Faber, PA Torjesen, P Hildebrandt, J Mehlsen and KF Hanssen
Department of Endocrinology, Aker University Hospital, Oslo, Norway. t.j.berg@ioks.uio.no

OBJECTIVE: Impairment of left ventricular diastolic function, possibly caused by increased collagen cross-linking of the cardiac muscle, is common in patients with type 1 diabetes even without coronary artery disease. Advanced glycation end products (AGEs) cross-link tissue collagen and are found within myocardial fibers. The aim of this study was to examine for a possible association between circulating AGEs and left ventricular cardiac function. RESEARCH DESIGN AND METHODS: Left ventricular diastolic and systolic function were assessed by M-mode and Doppler echocardiography in 52 patients with type 1 diabetes, age 40 +/- 13 (mean +/- SD) years, diabetes duration 17 +/- 13 years, and HbA1c 8.3 +/- 1.1%. Serum levels of AGEs and N epsilon-(carboxymethyl)lysine (CML) were measured by newly developed competitive immunoassays. RESULTS: A positive correlation was found between serum levels of AGEs and isovolumetric relaxation time (IVRT), r = 0.46 (P < 0.0008), and left ventricular diameter during diastole, r = 0.37 (P < 0.008). The systolic parameters did not correlate with serum levels of AGEs. Stepwise regression analysis showed that 21% of the IVRT variation could be explained by serum levels of AGEs (F = 11.4, P < 0.002), whereas serum levels of CML, HbA1c, albumin excretion rate, diabetes duration, and mean arterial blood pressure were of no importance. AGE levels were significantly increased in men compared with women (P < 0.03) and present or former smokers (P < 0.04). CONCLUSIONS: Increased serum levels of AGEs, unlike serum levels of CML, are associated with heart stiffness in patients with type 1 diabetes, possibly mediated by the cross-linking properties of AGEs.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. J. SMIT, J. W. L. HARTOG, A. A. VOORS, and D. J. VAN VELDHUISEN Advanced Glycation Endproducts in Chronic Heart Failure Ann. N.Y. Acad. Sci., April 1, 2008; 1126(1): 225 - 230. [Abstract] [Full Text] [PDF]

				S.-Y. Goh and M. E. Cooper The Role of Advanced Glycation End Products in Progression and Complications of Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152. [Abstract] [Full Text] [PDF]

				L. van Heerebeek, N. Hamdani, M. L. Handoko, I. Falcao-Pires, R. J. Musters, K. Kupreishvili, A. J.J. Ijsselmuiden, C. G. Schalkwijk, J. G.F. Bronzwaer, M. Diamant, et al. Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension Circulation, January 1, 2008; 117(1): 43 - 51. [Abstract] [Full Text] [PDF]

				C. Hu, A. Dandapat, J. Chen, Y. Fujita, N. Inoue, Y. Kawase, K.-i. Jishage, H. Suzuki, T. Sawamura, and J. L. Mehta LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion Cardiovasc Res, November 1, 2007; 76(2): 292 - 302. [Abstract] [Full Text] [PDF]

				S. Boudina and E. D. Abel Diabetic Cardiomyopathy Revisited Circulation, June 26, 2007; 115(25): 3213 - 3223. [Abstract] [Full Text] [PDF]

				A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]

				P. M. Okin, R. B. Devereux, E. Gerdts, S. M. Snapinn, K. E. Harris, S. Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, L. H. Lindholm, et al. Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Circulation, March 28, 2006; 113(12): 1588 - 1596. [Abstract] [Full Text] [PDF]

				J. Asbun and F. J. Villarreal The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy J. Am. Coll. Cardiol., February 21, 2006; 47(4): 693 - 700. [Abstract] [Full Text] [PDF]

				V. M. MONNIER, D. R. SELL, and S. GENUTH Glycation Products as Markers and Predictors of the Progression of Diabetic Complications Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 567 - 581. [Abstract] [Full Text] [PDF]

				K. Chen, J. Chen, D. Li, X. Zhang, and J. L. Mehta Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-{gamma} Ligand Pioglitazone Hypertension, November 1, 2004; 44(5): 655 - 661. [Abstract] [Full Text] [PDF]

				B. E. Suys, N. Katier, R. P.A. Rooman, D. Matthys, L. Op De Beeck, M. V.L. Du Caju, and D. De Wolf Female Children and Adolescents With Type 1 Diabetes Have More Pronounced Early Echocardiographic Signs of Diabetic Cardiomyopathy Diabetes Care, August 1, 2004; 27(8): 1947 - 1953. [Abstract] [Full Text] [PDF]

				N. Nishikawa, T. Masuyama, K. Yamamoto, Y. Sakata, T. Mano, T. Miwa, M. Sugawara, and M. Hori Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1539 - 1545. [Abstract] [Full Text] [PDF]